Strengths include the use of a large, harmonized autopsy dataset with detailed neuropathologic and cognitive measures, enabling targeted analysis of neuritic plaque–negative, tau-positive individuals, a biologically distinct and underrepresented group in Alzheimer’s disease research. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.